Hebe Petiti-Martin G, Villar-Buill M, de la Hera I, Fuertes L, Burgués-Calderón M, Rivera-Díaz R, Vanaclocha F
Servicio de Dermatología, Hospital 12 de Octubre, Madrid España.
Actas Dermosifiliogr. 2013 Jan;104(1):67-70. doi: 10.1016/j.ad.2011.12.002. Epub 2012 Jun 15.
Thalidomide is the treatment of choice for severe or recurrent erythema nodosum leprosum. Its use has been associated with deep vein thrombosis in patients with blood disorders, however, particularly when used in combination with corticosteroids or chemotherapy. We describe a case of deep vein thrombosis in a 43-year-old man with lepromatous leprosy who was being treated with thalidomide and prednisone for a type 2 leprosy reaction (erythema nodosum leprosum); the patient also had transiently positive antiphospholipid antibody results. We stress the importance of considering deep vein thrombosis, a potentially fatal complication, in dermatology patients treated with thalidomide.
沙利度胺是重度或复发性麻风结节性红斑的首选治疗药物。然而，其使用与血液系统疾病患者的深静脉血栓形成有关，尤其是在与皮质类固醇或化疗联合使用时。我们描述了一名43岁瘤型麻风男性患者发生深静脉血栓形成的病例，该患者因2型麻风反应（麻风结节性红斑）正在接受沙利度胺和泼尼松治疗；该患者抗磷脂抗体结果也呈短暂阳性。我们强调，在接受沙利度胺治疗的皮肤病患者中，考虑深静脉血栓形成这一潜在致命并发症的重要性。
